Ginkgo Bioworks

Ginkgo Bioworks rallied in regular session, gaining 5.06% as of ET 09:47, driven by the launch of the ADME-One high-throughput ADME platform in partnership with Tangible Scientific and Inductive Bio, and the earlier AI drug discovery tie-up with ProQR. The stock climbed from a pre-market low of 10.18 to an intraday high of 10.80, breaking above the open of 10.53. Despite a 49.06% YoY revenue drop to $19.47M in Q1 and a net loss of $82.6M, the strategic refocus on core cell engineering and divestiture of the biosecurity unit have been well received. At 10.80, the stock sits above both MA20 ($9.013) and MA60 ($8.537), with a YTD gain of 24.14%, though it remains 38.57% below the 52-week high of $17.58. However, after-hours trading saw the price retreat to 10.091.